0
 

Transgenex Nanobiotech

 

Curing cancer with customized tests since 2012

 
 

Our technology targets the costly battery of cancer drug regimens causing patients to suffer side effects and at times catalyzing the growth of drug-resistant tumors. At TGN we individually assess each patient's tumor by creating the tumor outside the body, testing it with drugs and determining the most effective drug for the patient's treatment.

 
 
507609029_1280x720.jpg
 
 

 

 

Leadership

Founders


Dr. Shyam "Sam" Mohapatra
 

Sam is a distinguished professor of health and director of  The Center for Research and Education of Nanobioengineering at the University of South Florida. He also holds an MBA degree in international business from the University of South Florida. He is a Molecular Biologist with more than 20 years of experience in drug discovery for allergy diseases, including allergen and virally triggered asthma; he has been involved in several clinical trials and developed proprietary positions for treatment of respiratory diseases. Sam serves as an expert in peer review panels of several major national and international grant agencies, including the National Institute of Health. He has been a consultant to and performed collaborative and contract research for numerous pharmaceutical companies. He has received several awards for his inventions including the Global Corporate Award in Nanotechnology and election to the Florida Inventors Hall of Fame. Sam is a former recipient of the prestigious Pharmacia Allergy Research Foundation Award for Allergy Research

 

Dr. Subhra Mohapatra

Subhra has more than 15 years of experience in immunology and cell biology. After completing her PhD in immunology at the University of Manitoba she completed a National Cancer Institute of Canada Fellowship in the laboratory of Dr. Arnold Greenberg, the discoverer of NK cells at the Manitoba Institute of Cell Biology. She then joined Dr. Jack Pledger at the Moffitt Cancer Center as a research assistant professor. Her studies have been published in highly ranked journals; Subhra is named an inventor in several patents and patent applications. She presently serves as associate professor at USF’s Department of Molecular Medicine. 

 

Executives


Chandresh Saraiya, MD, President

Chandresh served formerly as chairman, CEO and most recently medical director and vice president of Global Business Development for Nanotech Diagnostics and Therapeutics Inc (NDT), a startup and privately held clinical research company located in Tampa, FL. At TGN Chandresh spearheads the clinical testing of the ‘Tumor-on-a-dish’ platform and evaluates its application for personalized cancer testing.  

 

Sagar Galwankar, MBBS, MD, MPH, Vice President of Global Business Development

Sagar joined TGN as its President in 2014, serving as acting president from 2013-2015. He completed his MBBS and MD from the University of Pune and his MPH at the University of South Florida; he is a board certified physician. He founded and served as CEO of the INDO-US Academic Initiative for Emergency and Trauma. Since 2009 he has held the position of managing director for NanoBiotech India Private Limited, a company involved in creating solutions for diagnosing medical diseases and devising better drug delivery systems geared towards novel therapeutic targets. 

 


Bernard SkerkowskiVice President of Finance

Bernard has over 25 years of accounting experience in both the private and public sector ranging from the banking industry to government auditing and from public practice to small business administration. He has been a certified general accountant since 1983 operating his own private practice for the past 12 years. He has practiced in both the US and Canada and is a certified tax advisor with the IRS.

 

Rajesh R Nair, MPharm PhD, Acting Vice President of Operations

Rajesh earned his PhD in pharmacology from the University of Houston and completed his post-doctoral training at the University of Texas MD Anderson Cancer Center and Moffitt Cancer Center. He served as lead researcher at Modulation Therapeutics, Inc where he conducted pharmacodynamics and pharmacokinetic pre-clinical studies for the novel anti-myeloma peptide MTI-101.

 

Advisory Board


Michael Fountain, PhD, MBA

As director of the USF Center for Entrepreneurship Michael has focused for the past 20 years on creating, financing, and growing biotech companies. Michael’s achievements include holding numerous professorships at the USF College of Pharmacy and College of Engineering to name a few. Michael is named as an inventor on over 100 patents issued both in the U.S. and around the world. He has taken 3 companies public, co-founded over four companies, is a founding member and fellow of the National Academy of Inventors, and a Justin Longenecker Fellow in the United States Association for Small Business and Entrepreneurship. 

 

Loren D. Walensky, MD, PhD

Loren is associate professor and director of the Cancer Chemical Biology Program at the Dana-Farber Cancer Institute in Boston, Massachusetts.  

 

Charles E. Cox, MD 

Charles is currently a McCann Foundation endowed professor of breast surgery at the University of South Florida and CEO of the Breast Health Clinical and Research Integrated Strategic Program (CRISP).  

 

Alan F. List, MD

Alan is the president and CEO of Moffitt Cancer Center, an NCI-designated comprehensive cancer center in Florida.  

 

Benjamin Djulbegovic, MD, PhD

Benjamin is a practicing hematologist/oncologist at USF and the Moffitt Cancer Center and distinguished health professor and director of evidence-based medicine.